INTRODUCTION AND OBJECTIVES: Gold standard treatment for muscle invasive bladder cancer (MIBC) is radical cystectomy (RC) with neoadjuvant chemotherapy (NAC). However, the survival benefit of NAC in unselected patients is considered modest (5-15%). Recently genomic studies identified intrinsic basal, p53-like, and luminal molecular subtypes of MIBC which identify the genetic heterogeneity of bladder cancer. We hypothesized that tumor intrinsic subtype at the time of staging transurethral resection (TURBT) could be associated with clinical benefit from NAC.
INTRODUCTION AND OBJECTIVES: Gold standard treatment for muscle invasive bladder cancer (MIBC) is radical cystectomy (RC) with neoadjuvant chemotherapy (NAC). However, the survival benefit of NAC in unselected patients is considered modest (5-15%). Recently genomic studies identified intrinsic basal, p53-like, and luminal molecular subtypes of MIBC which identify the genetic heterogeneity of bladder cancer. We hypothesized that tumor intrinsic subtype at the time of staging transurethral resection (TURBT) could be associated with clinical benefit from NAC.
METHODS: We identified patients with MIBC who underwent RC with or without NAC between 2000 and 2010 at three different institutions. Whole-genome analysis was performed on TURBT specimens and were classified into basal, luminal or p53-like subtypes. Primary outcome is overall survival (OS). Secondary outcome is response is tumor downstaging (<pT2 at RC).
RESULTS: 273 TURBT specimens were analyzed. There were no significant differences in the subtypes between age, sex and stage (p<0.05). 87 (32%) were basal, 95 (35%) were p53-like, and 91 (33%) were luminal. 127 (46%) did not get NAC, and 146 (54%) received NAC. Downstaging occurred in 69 of 273 patients (26%), 2% (2/127) did not receive NAC and 47% (69/146) received NAC (p<0.001). Of patients that received NAC, 51% (25/49) of basal, 33% (16/48) p53-like, and 57% (28/49) of luminal tumors were downstaged (p¼0.033). Median OS for patients who did not receive NAC was 33 mo. vs. 102 mo. for those who did (p<0.0001). OS was improved for patients who did vs. those who did not get NAC in basal subtypes (17 mo. vs. 271 mo., p<0.001). However, there was no significant difference in OS for p53-like (58 mo. vs. 70 mo., p¼0.3137), and for luminal (43 mo. vs. 85 mo., p¼0.0629). For patients that did get NAC, patients with basal tumors had a significant increase in OS over to the other subtypes (p¼0.0239) ( Figure 1 ). CONCLUSIONS: Basal tumors in the absence of NAC are high risk, but they have a favorable response to NAC which results in an increased OS. Luminal tumors have a favorable downstage rate at RC, but this does not translate into increased OS. P53-like tumors have a poor prognosis regardless of use of NAC. We demonstrate that the intrinsic molecular subtypes of MIBC identified at TURBT have variable response to NAC with significant implications on OS.
Source of Funding: National Cancer Institute SPORE & VF Foundation

PD62-04 SAFETY AND EFFICACY GEMCITABINE-CISPLATIN SPLIT DOSE AS A NEOADUVANT CHEMOTHERAPY FOR MUSCLE INVASIVE BLADDER CANCER
Mohamed Abdelhafez*, Assuit, Egypt; Michael Williams, Norfolk, VA INTRODUCTION AND OBJECTIVES: Neoadjuvant chemotherapy (NAC) (Cisplatin based) and radical cystectomy are currently level 1 recommendation for muscle invasive bladder cancer. Gemcitabine-Cisplatin regimens are gaining popularity as (NAC). Only few data at present about splitting the doses in order to decrease toxicity, used with patients with lower renal function and achieve more patient compliance. The objective of this study is to study the effectiveness and safety of split dose Gemcitabine and Cisplatine as a NAC for muscle invasive bladder cancer.
METHODS: All consecutive patients from 2004 to 2015 that received Gemcitabine and Cisplatine split doses and followed by open radical cystectomy for T2-T4 bladder cancer were included in the study. All patients administered 1,000 mg/m2 of gemcitabine and 35 mg/m2 of Cisplatin given on days 1 and 8 of a 21 days cycle for 4 cycles. Preoperative patients' clinical parameters, need for dose reduction, number of cycles complications of NAC and pathologic response were recorded. Patients with unavailable follow up data were excluded from the study. Fisher exact test was used for univariate analysis to detect preoperative factors affecting pathologic response.
RESULTS: Eighty two patients met the inclusion criteria. Only 10 patents (12 %) couldn't complete 4 cycles because of complications. 38 patients (46%) were down staged (pT 1) and 32 achieved complete response (pT0). Median follow up time was 29 months. Univariate analysis for detecting factors affect pathologic response showed no significant effect of Gender (p¼0.742), race (p¼0.783), Age (p¼0.377), BMI (p¼0.821), T stage (0.982), N stage (0.615), presence of Cis (0.096), squamous differentiation (p¼0.229) and presence of lymphovasular invasion (p¼0.749).
CONCLUSIONS: Splitting the dose of Gemcitabine and Cisplatine as a NAC for muscle invasive bladder cancer has a good pathologic response with high safety profile. Patients with different preoperative characters can get benefit from this regimen.
Source of Funding: None
PD62-05 NEOADJUVANT CHEMOTHERAPY IN MUSCLE-INVASIVE BLADDER CANCER: DIFFERENCES IN CLINICAL AND PATHOLOGICAL RESPONCE
Andrea Benedetto Galosi*, Giulio Milanese, Ancona, Italy; Lucio Giustini, Fermo, Italy; Giulia Sbrollini, Isabella Chiodega, Ancona, Italy; Guevar Maselli, Fermo, Italy; Luciano Burattini, Rossana Berardi, Rodolfo Montironi, Ancona, Italy INTRODUCTION AND OBJECTIVES: Neoadjuvant cisplatinbased chemotherapy prior to radical cystectomy (RC) for muscle invasive bladder cancer is underutilized beside has been supported by guidelines. This study was undertaken to determine the rate of neoadjuvant gemcitabine and cisplatin (NGC) use before radical cystectomy (RC) and lymphadenectomy and to assess its effect on the pathologic response rates, surgical outcome and complication rate.
METHODS: This retrospective study examined all patients having a RC between January 2012 and September 2016. We collected patient demographics, pre-treatment clinical stage, post-RC pathologic data and survival data. Response Evaluation Criteria in Solid Tumors (RECIST, ver. 1.0) was used to asses clinical response to NGC (CR for complete response, PR for partial response, PD for progression of disease and SD for Stable disease on CT). Pathological Tumor Regression Grade (TRG) was evaluated (AJSP).
RESULTS: A total of 84 RC were performed of which 74 (88%) were for stage cT2-T4 urothelial carcinoma of the bladder. Salvage cystectomy were excluded (n¼10). Of the 74 patients, 30 (40.5%) received NGC. Based on CT scan, clinical response to NGC was e1194 THE JOURNAL OF UROLOGY â Vol. 197, No. 4S, Supplement, Monday, May 15, 2017 
